PriceTargets.com logo

Mind Medicine (MindMed) - MNMD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.20
  • Forecasted Upside: 195.77%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$8.52 As of 04/26/2024 06:45 PM ET
+0 (0.00%)

This chart shows the closing price for MNMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mind Medicine (MindMed) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNMD

Analyst Price Target is $25.20
▲ +195.77% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $25.20, with a high forecast of $75.00 and a low forecast of $7.00. The average price target represents a 195.77% upside from the last price of $8.52.

This chart shows the closing price for MNMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Mind Medicine (MindMed). This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2024Leerink PartnrsReiterated RatingOutperformLow
4/15/2024SVB LeerinkInitiated CoverageOutperform$20.00Low
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00Low
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00Low
2/29/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$14.00 ➝ $15.00Low
12/5/2023Canaccord Genuity GroupInitiated CoverageBuy$9.00Low
10/23/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00Low
8/4/2023HC WainwrightReiterated RatingBuy$75.00Low
8/4/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$5.00 ➝ $7.00Low
4/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$21.00Low
4/14/2023OppenheimerReiterated RatingOutperform$22.00Low
3/16/2023HC WainwrightReiterated RatingBuy$75.00Low
3/10/2023EF Hutton Acquisition Co. IReiterated RatingBuy$21.00Low
3/10/2023Royal Bank of CanadaReiterated RatingOutperform$5.00N/A
1/19/2023HC WainwrightReiterated RatingBuy$75.00Low
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$21.00Low
12/15/2022UBS GroupInitiated CoverageBuy$21.00Low
12/9/2022Roth CapitalReiterated RatingBuy$25.00Low
11/21/2022Canaccord Genuity GroupLower Target$22.00 ➝ $18.00Low
11/16/2022Royal Bank of CanadaInitiated CoverageOutperformLow
11/14/2022Maxim GroupLower Target$22.50 ➝ $8.00Low
10/4/2022Canaccord Genuity GroupLower TargetBuy$60.00 ➝ $22.00Low
9/21/2022HC WainwrightBoost TargetBuy$75.00Low
8/30/2022OppenheimerBoost Target$3.50 ➝ $52.00Low
8/25/2022OppenheimerInitiated CoverageOutperformLow
8/16/2022HC WainwrightLower TargetBuy$150.00 ➝ $75.00Low
8/10/2022Cantor FitzgeraldInitiated CoverageOverweight$45.00Low
5/23/2022HC WainwrightReiterated RatingBuy$150.00Low
5/4/2022Roth CapitalInitiated CoverageBuy$105.00Medium
8/5/2021HC WainwrightInitiated CoverageBuy$150.00Low
6/28/2021Maxim GroupInitiated CoverageBuy$90.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/29/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 13 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 11 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 11 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Mind Medicine (MindMed) logo
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $8.52
Low: $8.36
High: $8.76

50 Day Range

MA: $8.39
Low: $4.62
High: $11.75

52 Week Range

Now: $8.52
Low: $2.41
High: $12.22

Volume

649,578 shs

Average Volume

1,888,242 shs

Market Capitalization

$598.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Mind Medicine (MindMed)?

The following Wall Street research analysts have issued stock ratings on Mind Medicine (MindMed) in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, Leerink Partnrs, Royal Bank of Canada, and SVB Leerink LLC.
View the latest analyst ratings for MNMD.

What is the current price target for Mind Medicine (MindMed)?

5 Wall Street analysts have set twelve-month price targets for Mind Medicine (MindMed) in the last year. Their average twelve-month price target is $25.20, suggesting a possible upside of 195.8%. HC Wainwright has the highest price target set, predicting MNMD will reach $75.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $7.00 for Mind Medicine (MindMed) in the next year.
View the latest price targets for MNMD.

What is the current consensus analyst rating for Mind Medicine (MindMed)?

Mind Medicine (MindMed) currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MNMD will outperform the market and that investors should add to their positions of Mind Medicine (MindMed).
View the latest ratings for MNMD.

What other companies compete with Mind Medicine (MindMed)?

Other companies that are similar to Mind Medicine (MindMed) include Canopy Growth, biote, Aurora Cannabis, USANA Health Sciences and Cronos Group. Learn More about companies similar to Mind Medicine (MindMed).

How do I contact Mind Medicine (MindMed)'s investor relations team?

The company's listed phone number is 650-208-2454 and its investor relations email address is [email protected]. The official website for Mind Medicine (MindMed) is www.mindmed.co. Learn More about contacing Mind Medicine (MindMed) investor relations.